European forum on antiphospholipid antibodies: Research in progress

Lupus

Volumn 18, Issue 10, 2009, Pages 924-929

  Meroni, Pier Luigi ^a,g   Tincani, A ^b   Alarcon Riquelme M E ^c,d,e   Shoenfeld, Y ^f   Borghi, M O ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UPPSALA UNIVERSITY   (Sweden)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^e UNIVERSITY OF GRANADA   (Spain)

^f TEL AVIV UNIVERSITY   (Israel)

^g Ospedale San Luca   (Italy)

Author keywords

Antiphospholipid antibodies; Beta2 glycoprotein I; Complement; Genetics; Inflammation; Pregnancy

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; BETA2 GLYCOPROTEIN 1 ANTIBODY; EPITOPE; INTERFERON REGULATORY FACTOR 5; PHOSPHOLIPID ANTIBODY; STAT4 PROTEIN; VITAMIN D;

ANTIBODY DETECTION; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; COMPLEMENT ACTIVATION; DISEASE ASSOCIATION; DNA POLYMORPHISM; HUMAN; INFERTILITY; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PREGNANCY COMPLICATION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THROMBOSIS; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

ABORTION, SPONTANEOUS; ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CHOLECALCIFEROL; EUROPE; FEMALE; HUMANS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; RISK FACTORS;

EID: 68949186587     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309106916     Document Type: Article

References (38)

1. Rotar Z Rozman B de Groot PG et al. Sixth meeting of the European Forum on Antiphospholipid Antibodies. How to improve the understanding of the antiphospholipid syndrome. Lupus 2009; 18: 53-60.
2. Shoenfeld Y Meroni PL Toubi E. APS and SLE: Are they separate entities or just clinical presentations on the same scale. Curr Opin Rheumatol (in press).
3. Andreoli L Pregnolato F Burlingame RW et al. Antinucleosome antibodies in primary antiphospholipid syndrome: A hint at systemic autoimmunity. J Autoimmun 2008; 30: 51-57.
4. Arbuckle MR McClain MT Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533.
5. Harley JB Alarcon-Riquelme ME Criswell LA et al. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN). Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008; 40: 204-210.
6. Remmers EF Plenge RM Lee AT et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007; 357: 977-986.
7. Sigurdsson S Nordmark G Garnier S et al. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum Mol Genet 2008; 17: 2868-2876.
8. Taylor KE Remmers EF Lee AT et al. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet 2008; 4: E1000084.
9. Hom G Graham RR Modrek B et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008; 358: 900-909.
10. Kozyrev SV Abelson AK Wojcik J et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet 2008; 40: 211-216.
11. Abelson, AK, Delgado-Vega, AM, Kozyrev, SV, et al. STAT4 Associates with SLE through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis 2008 [Epub ahead of print].
12. Fischetti F Durigutto P Pellis V et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106: 2340-2346.
13. Pierangeli SS Chen PP Raschi E et al. Antiphospholipid antibodies and the antiphospholipid syndrome: Pathogenic mechanisms. Semin Thromb Hemost 2008; 34: 236-250.
14. Cervera R Asherson RA Acevedo ML et al. Antiphospholipid syndrome associated with infections: Clinical and microbiological characteristics of 100 patients. Ann Rheum Dis 2004; 63: 1312-1317.
15. Pierangeli SS Vega-Ostertag ME Raschi E et al. Toll-like receptor and antiphospholipid mediated thrombosis: In vivo studies. Ann Rheum Dis 2007; 66: 1327-1333.
16. De Angelis V Scurati S Raschi E et al. Pro-inflammatory genotype as a risk factor for aPL-associated thrombosis: Report of a family with multiple anti-phospholipid positive members. J Autoimmun 2009; 32: 60-63.
17. Shoenfeld Y Blank M Cervera R Font J Raschi E Meroni PL. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 2006; 65: 2-6.
18. Sjöberg BG Su J Dahlbom I et al. Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. Atherosclerosis 2009; 203: 528-532.
19. Su J Hua X Concha H Svenungsson E Cederholm A Frostegård J. Natural antibodies against phosphorylcholine as potential protective factors in SLE. Rheumatology (Oxford) 2008; 47: 1144-1150.
20. Arnson Y Amital H Shoenfeld Y. Vitamin D and autoimmunity: New etiological and therapeutical considerations. Ann Rheum Dis 2007; 66: 1137-1142.
21. Salmon JE Girardi G. Antiphospholipid antibodies and pregnancy loss: A disorder of inflammation. J Reprod Immunol 2008; 77: 51-56.
22. Stone S Pijnenborg R Vercruysse L et al. The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta 2006; 27: 457-467.
23. Shamonki JM; Salmon JE; Hyjek E; Baergen RN;. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007;196: 167.e1-167.e
24. Cavazzana I Nebuloni M Cetin I et al. Complement activation in anti-phospholipid syndrome: A clue for an inflammatory process. J Autoimmun 2007; 28: 160-164.
25. Park AL. Placental pathology in antiphospholipid syndrome. In: MA Khamashta, (ed), Hughes' syndrome. London: Springer-Verlag; 2006 p. 362-374.
26. de Laat B Wu XX van Lummel M Derksen RH de Groot PG Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 2007; 109: 1490-1494.
27. Tincani A Spatola L Prati E et al. The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species' evolution. J Immunol 1996; 157: 5732-5738.
28. Cucnik S Kveder T Krizaj I Rozman B Bozic B. High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis 2004; 63: 1478-1482.
29. Shoenfeld Y Gerli R Doria A et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-3347.
30. Doria A Sherer Y Meroni PL Shoenfeld Y. Inflammation and accelerated atherosclerosis: Basic mechanisms. Rheum Dis Clin North Am 2005; 31: 355-362.
31. Jimenez S Garcia-Criado MA Tassies D et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 2005; 44: 756-761.
32. Ames PR Margarita A Sokoll KB Weston M Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: Preliminary data. Ann Rheum Dis 2005; 64: 315-317.
33. Ohlenschlaeger T Garred P Madsen HO Jacobsen S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 2004; 351: 260-267.
34. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 2004; 114: 593-595.
35. Farzaneh-Far A Roman MJ Lockshin MD et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum 2006; 54: 3918-3925.
36. Ames PR Antinolfi I Scenna G Gaeta G Margaglione M Margarita A. Atherosclerosis in thrombotic primary antiphospholipid syndrome. J Thromb Haemost 2009; 7: 537-542.
37. Asanuma Y Oeser A Shintani AK. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Eng J Med 2003; 349: 2407-2415.
38. Roman MJ Shanker BA Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-2406.